American Brain Tumor Association president and CEO, Elizabeth Wilson, commented, “We are excited that combination therapy with Optune plus temozolomide continues to show a meaningful extension of long-term survival for newly diagnosed GBM patients”.
The device, which costs $21,000 (£16,800) a month, has been developed by a Jersey-based company Novocure and is sold in the US, Germany, Switzerland and Japan to adults with glioblastoma multiforme, an aggressive cancer.Dr. Roger Stupp, professor of Neurological Surgery at Northwestern University, is excited by the study’s findings.
Novocure justifies the price tag by citing the 17 years of research and development but they will make the treatment free for patients on Medicaid. Those who used the cap had a median overall survival of 21 months, compared to 16 months for those who didn’t. Unfortunately Optune does not come cheap at $700 a day.